Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.63USD
19 Sep 2018
Change (% chg)

$-0.02 (-1.21%)
Prev Close
$1.65
Open
$1.66
Day's High
$1.70
Day's Low
$1.63
Volume
249,895
Avg. Vol
205,024
52-wk High
$2.88
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Trevena Says Co, Pharmbio Korea Have Entered Into License Agreement For Development & Commercialization Of Oliceridine In S. Korea
Friday, 27 Apr 2018 08:03am EDT 

April 27 (Reuters) - Trevena Inc ::TREVENA - CO, PHARMBIO KOREA HAVE ENTERED INTO LICENSE AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION IN SOUTH KOREA OF CO'S PRODUCT OLICERIDINE.TREVENA INC - UNDER AGREEMENT WITH PHARMBIO KOREA, TREVENA WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.TREVENA - OLICERIDINE IS CURRENTLY UNDER REVIEW BY U.S. FDA FOR POTENTIAL APPROVAL IN U.S. FOR MANAGEMENT OF MODERATE-TO-SEVERE ACUTE PAIN.  Full Article

Trevena Reports Q4 Loss Per Share $0.24
Wednesday, 7 Mar 2018 07:00am EST 

March 7 (Reuters) - Trevena Inc ::TREVENA REPORTS FULL YEAR 2017 EARNINGS.Q4 LOSS PER SHARE $0.24.COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $66.1 MILLION AS OF DECEMBER 31, 2017.TREVENA-EXPECTS CURRENTLY AVAILABLE CASH, CASH EQUIVALENTS,&MARKETABLE SECURITIES, WITH INTEREST THEREON, TO BE ENOUGH TO FUND OPERATIONS INTO Q2 2019.Q4 EARNINGS PER SHARE VIEW $-0.27 -- THOMSON REUTERS I/B/E/S.  Full Article

Trevena Inc Says FDA Indicated To Co That PDUFA Date For Olinvo NDA Is Nov 2‍​
Friday, 5 Jan 2018 04:17pm EST 

Jan 5 (Reuters) - Trevena Inc ::TREVENA INC - ON JAN 5, FDA INDICATED TO THE CO THAT PDUFA REVIEW DATE FOR OLINVO NDA IS NOV 2‍​.TREVENA SAYS FDA ALSO INDICATED IT PLANS TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA​ - SEC FILING.  Full Article

Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection
Tuesday, 2 Jan 2018 04:01pm EST 

Jan 2 (Reuters) - Trevena Inc ::TREVENA ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR OLINVO (OLICERIDINE) INJECTION.SAYS EXPECTS THAT PDUFA DATE FOR NDA WILL BE IN Q4 OF 2018.  Full Article

Trevena Inc says Q3 loss per share $0.27
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Trevena Inc -:Trevena reports third quarter 2017 financial results and announces new positive clinical trial data.Q3 loss per share $0.27.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Trevena Inc - ‍expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months​.  Full Article

Trevena announces submission of NDA to U.S. FDA for Olinvo
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Trevena Inc :Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection).Trevena Inc - "‍look forward to working with FDA during review process and to a potential NDA approval of Olinvo in 2018"​.  Full Article

Trevena announces restructuring to focus resources on commercial strategy
Wednesday, 11 Oct 2017 04:01pm EDT 

Oct 11 (Reuters) - Trevena Inc :Trevena announces restructuring to focus resources on commercial strategy.Trevena Inc - ‍new drug application for olinvo remains on track​.‍New Drug Application for Olinvo remains on track for submission in October​.Trevena Inc - ‍company is reducing its workforce by approximately 30 percent, or 21 full time employees​.Trevena Inc - ‍company continues to expect to report data later this year from ongoing phase 1 study of TRV250​.Trevena Inc - ‍also expects to incur a charge in Q4 of 2017 of approximately $2.0 million related to reduction ​.Trevena inc - ‍company expects to report cash, cash equivalents and marketable securities as of September 30, 2017 of approximately $76.7 million​.Trevena-Intends to complete ongoing Phase 1 trial of TRV250 for acute migraine, will also assess options for further development of asset.Trevena - ‍estimates workforce reduction, other initiatives, will reduce cash expected to be used in activities over next 3 calendar years by about $40 million​.Trevena Inc - ‍company expects cash, cash equivalents and marketable securities will be sufficient to support operations into Q4 of 2018.Trevena INC - ‍intends to complete ongoing Phase 1 trial of TRV250 for acute migraine​.  Full Article

Trevena Q2 loss per share $0.35
Thursday, 3 Aug 2017 07:00am EDT 

Aug 3 (Reuters) - Trevena Inc ::Trevena reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.35.Q2 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Trevena Inc says olinvo program on track for NDA submission in September/October 2017.  Full Article

Trevena Q1 loss per share $0.36
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Trevena Inc :Trevena reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.36.Q1 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

Trevena reports presentation of positive results from two phase 3 pivotal efficacy studies of olinvo
Thursday, 6 Apr 2017 07:00am EDT 

Trevena Inc : Trevena-Announced presentation of positive results from two phase 3 pivotal efficacy studies of olinvo . Trevena Inc - data showed significant efficacy of olinvo in managing moderate-to-severe acute pain . Trevena - data included head-to-head comparisons to iv morphine suggesting olinvo could be new analgesic option for patients at risk of opioid-related aes . Trevena - "results suggest that olinvo can be dosed to manage moderate-to-severe acute pain, so that patients may titrate opioid dosing as needed" . Trevena Inc - results from studies recapitulate earlier clinical trial results .Trevena Inc - on track to submitting new drug application to FDA for olinvo in Q4 of this year.  Full Article

BRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer

* TREVENA APPOINTS MARK A. DEMITRACK, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: